The SRC/ABL inhibitor BMS-354825 overcomes resistance to imatinib mesylate in chronic myelogenous leukemia cells through multiple mechanisms.

被引：4
|
作者：
Donato, NJ
Wu, J
Kong, LY
Lee, F
Talpaz, M
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Bristol Myers Squibb, Canc Therapeut, Princeton, NJ USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
10.1182/blood.V104.11.1989.1989
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1989
引用
收藏
页码：549A / 549A
页数：1
相关论文
共 50 条
  • [31] Correlation of clinical response to dasatinib (BMS-354825) with BCR-ABL mutation status in imatinib-resistant patients (pts) with chronic myeloid leukemia (CML) treated at MD Anderson cancer center (MDACC).
    Jabbour, E
    Cortes, J
    Talpaz, M
    Jones, D
    O'Brien, S
    Nicaise, C
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 318A - 318A
  • [32] Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
    Lei, Hu
    Xu, Han-Zhang
    Shan, Hui-Zhuang
    Liu, Meng
    Lu, Ying
    Fang, Zhi-Xiao
    Jin, Jin
    Jing, Bo
    Xiao, Xin-Hua
    Gao, Shen-Meng
    Gao, Feng-Hou
    Xia, Li
    Yang, Li
    Liu, Li-Gen
    Wang, Wei-Wei
    Liu, Chuan-Xu
    Tong, Yin
    Wu, Yun-Zhao
    Zheng, Jun-Ke
    Chen, Guo-Qiang
    Zhou, Li
    Wu, Ying-Li
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [33] Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia
    Hu Lei
    Han-Zhang Xu
    Hui-Zhuang Shan
    Meng Liu
    Ying Lu
    Zhi-Xiao Fang
    Jin Jin
    Bo Jing
    Xin-Hua Xiao
    Shen-Meng Gao
    Feng-Hou Gao
    Li Xia
    Li Yang
    Li-Gen Liu
    Wei-Wei Wang
    Chuan-Xu Liu
    Yin Tong
    Yun-Zhao Wu
    Jun-Ke Zheng
    Guo-Qiang Chen
    Li Zhou
    Ying-Li Wu
    Nature Communications, 12
  • [34] Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance
    L Truitt
    C Hutchinson
    J F DeCoteau
    C R Geyer
    Oncogenesis, 2014, 3 : e122 - e122
  • [35] Chaetocin antileukemia activity against chronic myelogenous leukemia cells is potentiated by bone marrow stromal factors and overcomes innate imatinib resistance
    Truitt, L.
    Hutchinson, C.
    DeCoteau, J. F.
    Geyer, C. R.
    ONCOGENESIS, 2014, 3 : e122 - e122
  • [36] Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms
    Dai, Y
    Rahmani, M
    Pei, XY
    Dent, P
    Grant, S
    BLOOD, 2004, 104 (02) : 509 - 518
  • [37] Chaetocin Anti-Leukemia Activity Against Chronic Myelogenous Leukemia Stem Cells Is Potentiated By Bone Marrow Stromal Factors and Overcomes Innate Imatinib Resistance
    Truitt, Luke
    Hutchinson, Catherine
    Mochoruk, Karen
    DeCoteau, John F.
    Geyer, C. Ronald
    BLOOD, 2014, 124 (21)
  • [38] The dual SRC/ABL kinase inhibitor BMS-354825 potently inhibits the growth of myeloid leukemic cells characterized by FIt3-ITD expression, GM-CSF dependency, or G-CSF responsiveness via an ABL-independent mechanism
    Kanerva, J
    Nwawka, O
    Hwang, K
    Lee, FY
    Corey, SJ
    BLOOD, 2004, 104 (11) : 203B - 203B
  • [39] Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment
    Chu, S
    Xu, H
    Shah, NP
    Snyder, DS
    Forman, SJ
    Sawyers, CL
    Bhatia, R
    BLOOD, 2005, 105 (05) : 2093 - 2098
  • [40] Rare Frameshift Mutation Cys475Tyrfs☆11 in the BCR/ABL Kinase Domain Contributes to Imatinib Mesylate Resistance in 2 Korean Patients with Chronic Myelogenous Leukemia
    Park, Sang Hyuk
    Chi, Hyun-Sook
    Kwon, Mi-Ryang
    Cho, Young-Uk
    Jang, Seongsoo
    Park, Chan-Jeoung
    ANNALS OF LABORATORY MEDICINE, 2012, 32 (06) : 452 - 454
12345